Results 81 to 90 of about 16,037 (203)
Contact Dermatitis, Volume 95, Issue 3, Page 237-275, September 2026.ABSTRACT The present guideline updates the initial ESCD patch testing guideline, summarizing all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed‐type hypersensitivity skin and mucosal conditions. Sections with brief descriptions
Wolfgang Uter +23 more
wiley +1 more source
International Journal of Dermatology, Volume 65, Issue 9, Page 1846-1855, September 2026.ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo +11 more
wiley +1 more source
ACR Open Rheumatology, Volume 8, Issue 8, August 2026.Objective To evaluate the six‐month effectiveness and safety of rituximab biosimilars compared to the originator in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and outcomes following originator to biosimilar switching. Methods We recruited adults with GPA or MPA treated with the rituximab originator or a biosimilar for ...
Arielle Mendel +14 more
wiley +1 more source
Ibom Medical JournalBackground: The burden of allergic diseases and conjunctivitis has been on the increase, especially in developing countries, prompting several studies across varying populations to investigate the causes and prevalence of these conditions ...
Okoro CC, Odigie OM, Ozigis M
doaj +4 more sources
Clinical Ophthalmology, 2020 Elizabeth Yeu,1 Scott Hauswirth2 1Virginia Eye Consultants, Norfolk, VA, USA; 2Department of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO, USACorrespondence: Elizabeth YeuVirginia Eye Consultants ...
Yeu E, Hauswirth S
doaj
Clinical and Translational Allergy, Volume 16, Issue 8, August 2026.Expert consensus using a Delphi methodology proposed definitions of control and remission for allergic rhinitis, conjunctivitis and asthma in the context of allergen immunotherapy. These consensus‐based criteria integrate symptoms, medication use, patient‐reported outcomes and objective measures to support a more structured assessment of treatment ...
Eloína González‐Mancebo +11 more
wiley +1 more source
Clinical OphthalmologyAmber N Piazza,1 Peter A Downie,1,2 Michael S Lee,3 Bruce R Lindgren,4 Joshua H Olson3 1Medical School, University of Minnesota, Minneapolis, MN, 55455, USA; 2Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI ...
Piazza AN +4 more
doaj
Clinical and Translational Allergy, Volume 16, Issue 8, August 2026.ABSTRACT Background Dupilumab is effective for moderate‐to‐severe atopic dermatitis (AD), but sustained disease control after treatment discontinuation remains challenging. House dust mite allergen immunotherapy (HDM‐AIT) may provide disease‐modifying effects in sensitized patients, but the added value of combining HDM‐AIT with dupilumab remains ...
Jiale Lian +3 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background Non‐typeable Streptococcus pneumoniae (NT‐Sp) strains lack detectable capsules and are often missed by traditional serotyping. While associated primarily with asymptomatic carriage, NT‐Sp has emerged as a key player in antimicrobial resistance (AMR) gene dissemination and serotype replacement in the post‐vaccine era. This systematic
Robert K. Reeks +2 more
wiley +1 more source
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Risa Fukuda +12 more
wiley +1 more source